Meet us at the 2024 World ADC Conference
SK pharmteco will be attending the 14th Annual World ADC (Antibody-Drug Conjugate)Â Conference in London, 12th – 15th March 2024. This
SK pharmteco offers integrated CDMO services across Cell and Gene Therapy, Small Molecule, and Analytical Services for drug substances and products
Built on 80 years of experience, SK pharmteco is a trusted partner specializing in the manufacture of APIs and intermediates, cell and gene therapy technologies, registered starting materials and analytical services for the pharmaceutical industry worldwide. Our global operations have the capability and capacity to support your needs from development through commercial production.
Our complementary assets and expertise enable us to provide the highest quality services to our customers.
SK pharmteco specializes in the commercial and clinical production of APIs, Advanced Intermediates, Registered Starting Materials, Key Building Blocks and Viral Vectors. Our offerings include process R&D, analytical method development and stability, scale-up and optimization, validation and commercial production. Additionally, we offer extensive Adeno-Associated Viral (AAV) and Lentiviral vector development and cGMP production capabilities.
Our global operations include 7 cGMP manufacturing and development facilities across the United States, Korea, Ireland and France. We also operate dedicated analytical services facilities.
SK pharmteco is a leader in operational excellence and continuous improvement. Our highly skilled team delivers innovative solutions utilizing advanced technologies:
We provide PAI and full regulatory support as well as complete confidentiality. We have a strong record of environmental, health, and safety performance. All our plants have been successfully audited by global regulatory agencies including the FDA (US), EMA (Europe), PMDA (Japan), and MFDS (Korea).Â
With a strong technology toolbox and ~1,000 m³ (~265,000 gal) of global small molecule capacity and two facilities dedicated to large molecules, we have the capability and capacity to support your needs across the full lifecycle.
The most trusted global partner in the delivery of innovative medicine
We are committed to changing the world through our unwavering dedication to life-saving therapies.
We enable our partners with cutting-edge technology, expertise and customer centricity, allowing them to bring breakthrough treatments to patients and delivering happiness and health to stakeholders everywhere.
Diazomethane, Azide, Hydrazine, Ozone
Fixed bed, CSTR, PAT
Process Development, CGT Analysis, Viral Vector Development & CGMP Manufacturing, Plasmid DNA Manufacturing, & Cell Therapy Manufacturing
Simulated Moving Bed (SMB), Batch
Up to 4 m3 (~1,000 gal) scale
Down to 10 ng/m3 containment
Schedule II-V Manufacturing
Schedule I By Request
Crystallization, MicronizationÂ
SK pharmteco will be attending the 14th Annual World ADC (Antibody-Drug Conjugate)Â Conference in London, 12th – 15th March 2024. This
We will again be attending DCAT Week, March 18-21, 2024, the premier global event held each year in New York
The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors
"*" indicates required fields